Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -101.76% is 17% above its 5-year average of -121.91%, near the high end of its 5-year range (-316.66%–-14.82%).
As of the fiscal period ended Tuesday, June 30, 2026. 4.51% below its 12-month average of -97.36%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -101.76%.
RETURN ON EQUITY (ROE)
-101.76%
RETURN ON EQUITY (ROE) AVG TTM
-97.36%
RETURN ON EQUITY (ROE) AVG 3Y
-175.70%
RETURN ON EQUITY (ROE) AVG 5Y
-121.91%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-4.51%
CURRENT VS 3Y AVG
+42.08%
CURRENT VS 5Y AVG
+16.53%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-37.16%
median of 398 covered companies
CURRENT VS SECTOR MEDIAN
-173.84%
vs the sector median at left
Bionano Genomics, Inc.
Market Cap
$16.58M
Return on Equity (ROE)
-101.76%
TTM Avg
-97.36%
3Y Avg
-175.70%
5Y Avg
-121.91%
Market Cap
$16.54M
Return on Equity (ROE)
N/A
TTM Avg
-416.37%
3Y Avg
-259.03%
5Y Avg
-190.00%
Market Cap
$16.22M
Return on Equity (ROE)
-271.81%
TTM Avg
-934.34%
3Y Avg
-347.56%
5Y Avg
-265.02%
Market Cap
$15.91M
Return on Equity (ROE)
-348.81%
TTM Avg
-160.92%
3Y Avg
-184.71%
5Y Avg
-151.29%
Market Cap
$15.30M
Return on Equity (ROE)
-951.92%
TTM Avg
-161.65%
3Y Avg
-122.41%
5Y Avg
-87.71%
Market Cap
$18.77M
Return on Equity (ROE)
N/A
TTM Avg
-3014.83%
3Y Avg
-1589.49%
5Y Avg
-1032.64%
Market Cap
$18.82M
Return on Equity (ROE)
-117.98%
TTM Avg
-84.94%
3Y Avg
-64.05%
5Y Avg
-76.29%
Market Cap
$14.28M
Return on Equity (ROE)
-69.47%
TTM Avg
-55.64%
3Y Avg
-44.95%
5Y Avg
-41.56%
Market Cap
$13.62M
Return on Equity (ROE)
-101.66%
TTM Avg
-140.38%
3Y Avg
-131.64%
5Y Avg
-101.94%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bionano Genomics, Inc. (BNGO) | $16.58M | -101.76% | -97.36% | -175.70% | -121.91% |
| Dyadic International, Inc. (DYAI)vs › | $16.54M | N/A | -416.37% | -259.03% | -190.00% |
| BioCardia, Inc. (BCDA)vs › | $16.22M | -271.81% | -934.34% | -347.56% | -265.02% |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.91M | -348.81% | -160.92% | -184.71% | -151.29% |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.30M | -951.92% | -161.65% | -122.41% | -87.71% |
| Estrella Immunopharma, Inc. (ESLA)vs › | $18.77M | N/A | -3014.83% | -1589.49% | -1032.64% |
| Cosmos Health Inc. (COSM)vs › | $18.82M | -117.98% | -84.94% | -64.05% | -76.29% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $14.28M | -69.47% | -55.64% | -44.95% | -41.56% |
| IN8bio, Inc. (INAB)vs › | $13.62M | -101.66% | -140.38% | -131.64% | -101.94% |
| Vyome Holdings, Inc. (HIND)vs › | $13.55M | -186.95% | 1198.98% | 241.18% | 112.17% |
ROE
-101.8%
ROA
-67.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -101.76% |
| 2026-03-31 | -84.34% |
| 2025-12-31 | -59.42% |
| 2025-09-30 | -77.49% |
| 2025-06-30 | -163.82% |
| 2025-03-31 | -173.69% |
| 2024-12-31 | -316.66% |
| 2024-09-30 | -277.86% |
| 2024-06-30 | -254.06% |
| 2024-03-31 | -274.00% |
| 2023-12-31 | -241.78% |
| 2023-09-30 | -190.99% |
| 2023-06-30 | -68.23% |
| 2023-03-31 | -60.38% |
| 2022-12-31 | -53.17% |
| 2022-09-30 | -41.48% |
| 2022-06-30 | -37.16% |
| 2022-03-31 | -29.71% |
| 2021-12-31 | -21.49% |
| 2021-09-30 | -17.92% |
| 2021-06-30 | -14.82% |
| 2021-03-31 | -11.18% |
| 2020-12-31 | -117.17% |
| 2020-09-30 | -254.00% |
| 2020-06-30 | -563.35% |
| 2019-12-31 | -825.05% |
| 2019-03-31 | -383.31% |
| 2018-12-31 | -182.46% |
| 2018-09-30 | -118.18% |
